Free Newsletter
Novartis' Gorsky to return to J&J
Well, we didn't have to watch Alex Gorsky (photo) for long. According to the Wall Street Journal, when Novartis said that the U.S. pharma CEO was leaving, they left out the part about his returning to alma mater Johnson & Johnson. Gorsky will be chairman of Ethicon, a J&J unit that makes surgical equipment and sutures. Gorsky left J&J to join Novartis in 2004.
Novartis also told the WSJ that Gorsky's exit had nothing to do with any of the changes new worldwide pharma chief Joe Jiminez is making at the company.
- check out the story in the Wall Street Journal
Related Articles:
U.S. CEO exits Novartis. Report
CEO: Novartis plans big restructuring. Report
Lagging sales spur Novartis layoffs. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: